Similar situation on the overweight portfolio, but the way the 3-Pillar strategic plan is shaping up for 2021 is not a year I will closing out my position.
1) THIS QUARTER: This quarter, but could be ANY DAY - update on all three pillars (each with their own value add)
2) END OF H1: Closer to Mid-year Start of POC for Breast cancer and AML, FTO pre-clinical work.
3) LATER 2021: Updates and potentially close to Read outs on Breast Cancer ~ Fingers crossed any early X-Mas present!
Whilst I expect the price to re-rate at each milestone, there will inevitably be short term profit takers / traders / bots that will create dips - especially during announcement free periods. This is expected! However, as a long term shareholder the strategy is on the big prize of a partnership or buyout that could happen from any time but, perhaps late 2021 / early 2022 at the earliest.
As mentioned by a number of others, this closes the CGT window and thus jumping in and out of RACE does not make sense to me in 2021. Rather accumulate and buy the dip aligns well as a LT holder.
DYOR not advice.
RAC - Charts & Price Action, page-3374
-
- There are more pages in this discussion • 19,558 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
